All In Biotech

Free tool

FAERS Monitor: Nilotinib D-Tartrate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218922 or its brand name (Nilotinib D-Tartrate, Nilotinib D-Tartrate). Reports on generic versions are filed under their own applications.

Reports

4,067

Serious

3,797

93% of reports

Hospitalization

811

Death reported

635

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug intolerance430
  • drug ineffective349
  • drug resistance348
  • diarrhoea338
  • dyspnoea335
  • fatigue325
  • nausea306
  • headache302
  • myalgia281
  • arthralgia272
  • abdominal pain271
  • pleural effusion270
  • pyrexia260
  • pruritus250
  • asthenia248

Reports by year received

View as table
YearReports
20074
200812
200917
201019
201143
201295
201388
2014154
2015157
2016215
2017177
2018267
2019440
2020375
2021347
2022323
2023306
2024365
2025341
2026322

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,092 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug resistanceSignal34871.064.223,655
drug intoleranceSignal43023.121.19,079
pleural effusionSignal27023.020.55,662
myalgiaSignal2818.67.61,881
abdominal painSignal2716.05.41,143
pyrexiaSignal2603.93.5564
astheniaSignal2483.43.0428
arthralgiaSignal2723.43.0463
pruritusSignal2503.43.0421
dyspnoeaSignal3353.12.8476
diarrhoeaSignal3382.72.4374
headacheSignal3022.52.2276
fatigueSignal3252.21.9209
nausea3062.01.8158
drug ineffective3491.41.237

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.